Caleobrol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Caleobrol

Quick Facts

Property Description
Active ingredient Calcitriol (1α,25-dihydroxyvitamin D3)
Form Capsule, Oral solution, Injectable solution
Pharmacological class Vitamin D Analog / Calcemic Agent
Common use Regulation of calcium and phosphate metabolism
Origin Synthetic derivative

What Type of Medicine is Caleobrol?

Caleobrol is a pharmaceutical product featuring the active ingredient Calcitriol, which is officially classified as a Vitamin D Analog and functions as a powerful Calcemic Agent. This compound is chemically identical to 1α,25-dihydroxyvitamin D3, the final and most active hormone form naturally generated by the body. The fundamental role of this molecule in mineral homeostasis is recognized as it bypasses the need for the body's natural metabolic conversion in the liver and kidneys. This characteristic distinguishes it from inactive vitamin D precursors and supports its position in therapeutic mineral management. Well-established global brands such as Rocaltrol and Calcijex also contain this same formulation of Calcitriol.

Composition and Available Forms of Calcitriol

The active ingredient is a manufactured synthetic derivative, ensuring precise purity and dosage consistency for this systemically active medication. Calcitriol is available in several high-level dosage forms, including softgel capsules, a clear oral solution typically formulated with an inert oil base, and an injectable solution for parenteral administration. The primary general use of Calcitriol involves regulating the absorption of calcium from the gastrointestinal tract and its utilization within the body.

What is the General Purpose of Calcitriol?

The general purpose of Calcitriol is to support and restore essential mineral balance by regulating calcium and phosphate metabolism throughout the body. The compound is used as a critical systemic therapy when the body's own synthesis of the active hormone is impaired—for example, in patients with long-term kidney issues. This mechanism is essential for maintaining systemic stability, ultimately supporting the structural integrity of the skeleton and maintaining neuromuscular function.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Caleobrol?

Possible Side Effects and Safety Information

The safety profile of Caleobrol, which contains the active ingredient Calcitriol, is closely related to its function as a powerful calcemic agent. Adverse reactions are primarily consequences of hypercalcemia (abnormally high blood calcium levels), which is the most frequent and expected side effect documented in official regulatory labeling.

Officially Documented Adverse Reactions

Adverse reactions are formally classified by frequency and grouped into System-Organ Classes (SOCs):

Classification Examples of Reactions Affected System-Organ Class
Very Common (ge 1/10) Hypercalcemia Metabolism and Nutrition Disorders
Common (ge 1/100 to <1/10) Headache, Nausea, Abdominal Pain, Rash, Hypercalciuria Nervous System, Gastrointestinal, Skin, Renal/Urinary
Uncommon (ge 1/1,000 to <1/100) Vomiting, Decreased Appetite, Blood Creatinine Increased Gastrointestinal, Metabolism and Nutrition

Serious Safety Considerations

Regulatory documents emphasize that sustained or chronic hypercalcemia can lead to serious adverse reactions. These include generalized vascular and soft-tissue calcification, such as nephrocalcinosis (calcium deposits in the kidney). Additionally, high calcium levels may contribute to the precipitation of cardiac arrhythmias, particularly in individuals already taking digitalis medication.

Safety-Related Restrictions and Patterns

The medicine is formally contraindicated in patients with pre-existing Hypercalcemia or any evidence of Vitamin D Toxicity. Official labeling distinguishes between Early Signs (acute effects like weakness and dry mouth) and Late Signs (chronic effects like polyuria and hypertension) of excessive vitamin D intake. Specific safety notes also apply to immobilized patients and those with renal failure, due to their heightened vulnerability to calcium dysregulation, as stated in official prescribing information.

Overdose and Emergency Response

The official regulatory profile for Caleobrol overdose centers on the risk of progressive hypercalcemia, which is considered dangerous and may necessitate emergency attention. This condition is the principal manifestation of toxicity and may result from the cumulative overdosage of the drug or its derivatives.

Documented signs of overdose are classified into early and late presentations. Early symptoms may include weakness, headache, somnolence, nausea, vomiting, and a metallic taste. Chronic or severe hypercalcemia can lead to late signs such as polyuria, polydipsia, weight loss, and hyperthermia. Laboratory findings associated with toxicity include hyperphosphatemia and the Ca x P product exceeding the critical regulatory threshold.

Severe outcomes are officially documented and include the risk of cardiac arrhythmias, especially in patients concurrently taking digitalis. Long-term toxicity can result in serious complications such as generalized vascular and soft-tissue calcification, and nephrocalcinosis.

If an overdose is suspected, regulatory authorities mandate that the medication must be discontinued immediately, and the patient must seek immediate medical attention. Supportive management, as described in official labeling, includes the withholding of all other Vitamin D products, maintaining adequate fluid intake, and implementing a low-phosphate diet with non-aluminum phosphate-binding compounds. Monitoring of serum calcium and phosphorus levels is required during the management period.

Therapeutic Uses of Caleobrol

What Caleobrol Treats: Main Uses and Benefits

Caleobrol is commonly used in conditions where the body requires active support for mineral regulation, focusing on restoring systemic stability and addressing symptoms related to chronic mineral and bone disorders.

Caleobrol is applied across therapeutic domains involving fundamental mineral dysregulation. This includes managing hypocalcemia (low calcium levels), secondary hyperparathyroidism associated with chronic kidney disease (CKD), and metabolic bone diseases such as renal osteodystrophy and certain forms of rickets or osteomalacia.

This supportive therapeutic benefit helps to support the structural integrity of the skeleton and is commonly used across conditions characterized by periods of heightened symptoms related to systemic imbalance.

“This medication is commonly applied in clinical contexts involving endocrine dysfunction and chronic systemic failure, where maintaining proper calcium and phosphate balance contributes to supporting general well-being.”

By providing the active agent, Caleobrol assists with maintaining functional stability and helps improve day-to-day comfort. It is applied in addressing persistent low calcium levels while easing associated manifestations of neuromuscular instability and muscle weakness.


Quick Fact: Supportive Relief for Mineral Disorders

Focus Benefit Category
Primary Use Context Mineral and bone disorders in chronic kidney disease and hypoparathyroidism.
Symptom Relief Easing associated bone pain and muscle weakness.
Patient Support Assists with maintaining functional stability during symptomatic periods.

Regulatory References

  1. Calcitriol - StatPearls - NCBI Bookshelf

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Caleobrol — official regulatory information

This section outlines the official criteria for who is eligible to use Caleobrol, based strictly on formal regulatory documents.

Classification Eligible Populations
Use Allowed Patients with hypocalcemia (low calcium) in the setting of chronic renal dialysis or hypoparathyroidism (postsurgical, idiopathic, or pseudohypoparathyroidism).
Age-Related Rules Use may be considered in pediatric patients (children) to maintain age-appropriate calcium levels, typically at adjusted dosages. Older adults may require cautious dosing due to potentially decreased organ function.

Classification Contraindicated/Restricted Populations
Contraindicated Patients with hypercalcemia (abnormally high calcium levels) or any evidence of Vitamin D toxicity. Also, individuals with a known hypersensitivity or allergy to the medicine or its ingredients.
Condition-Specific Restrictions Renal Impairment: Use is frequently indicated for specific chronic kidney disease stages, but careful monitoring is required. Hepatic Impairment: Studies are limited, and use should proceed with caution. Soft Tissue Calcification: Prohibited if the serum calcium and phosphorus product (Ca x P) exceeds a specified limit (typically 70 mg²/dL²).
Pregnancy/Lactation Pregnancy: Use is generally only recommended if the potential benefit justifies the potential risk to the fetus, as adequate studies are not available. Lactation: It is generally not recommended to breastfeed during treatment as the medicine may pass into breast milk.

Connection to the overall eligibility profile: Regulatory documents strictly define eligible patients as those with specific calcium and parathyroid-related disorders, provided they do not have pre-existing high calcium levels or vitamin D toxicity. The primary eligibility constraint is the presence of hypercalcemia, which prohibits use to prevent severe cardiovascular or soft-tissue complications. Special consideration and close monitoring of calcium and phosphorus levels are mandated for nearly all populations, including pediatric, older adult, and renally impaired patients, to manage the narrow therapeutic window.

What should I know about interactions with other medicines?

Caleobrol is an active form of Vitamin D and its action can be significantly affected by other medicines, supplements, and certain foods. Inform your healthcare provider of all prescription drugs, over-the-counter medicines, and nutritional supplements you are currently taking to allow for a comprehensive review of potential interactions.

Medications and Supplements to Discuss

Particular caution is required when Caleobrol is co-administered with any agents that influence calcium and phosphate levels in the body, which can increase the risk of hypercalcemia (high blood calcium) or other electrolyte disturbances.

  • Other Vitamin D Analogs and Supplements: Concurrent use of other vitamin D supplements or similar analogs should be avoided due to the significant risk of additive effects and toxicity, potentially leading to hypercalcemia.
  • Thiazide Diuretics: These medicines can reduce the excretion of calcium in the urine, and when combined with Caleobrol, the risk of developing hypercalcemia is increased.
  • Calcium- and Phosphate-Containing Products: This includes high-dose calcium supplements, certain phosphate-binding agents, and some antacids. Their simultaneous use with Caleobrol requires careful monitoring of serum calcium and phosphate levels.
  • Cardiac Glycosides (e.g., Digoxin): High calcium levels (hypercalcemia) can increase the risk of cardiotoxicity and arrhythmias, making caution and close monitoring essential if Caleobrol is used with this class of heart medication.
  • Enzyme-Inducing Anticonvulsants (e.g., Phenytoin, Phenobarbital): These drugs may accelerate the metabolism of Caleobrol, potentially reducing its concentration and therapeutic effect, which may necessitate a dose adjustment of Caleobrol.

Food and Other Interactions

Dietary intake is an important consideration. Patients should maintain the calcium and phosphate intake recommended by their doctor. Rapid or significant changes in diet, particularly in the consumption of calcium-rich or vitamin D-fortified foods, should be avoided. Grapefruit and grapefruit juice may also affect the blood levels of Caleobrol and should be consumed only under medical guidance.

Mechanism of Action

Caleobrol operates through a dual-action mechanism to regulate excessive nerve signaling, targeting ion channels essential for initiating and transmitting electrical impulses.

Targeted Blockade of Peripheral Signal Generation

This domain covers Caleobrol's primary action as a state-dependent blocker of the Na v1.7 Voltage-Gated Sodium Channel. By preferentially binding to hyperactive peripheral sensory neurons ( C- and Adelta-fibers), it stabilizes the channel in an inactivated state, thereby reducing the generation and propagation of electrical signals from the periphery to the central nervous system.

Central Modulation of Signal Processing

This secondary domain involves the drug's effect as a modulator/inhibitor of the Ca v3.2 T-type Calcium Channel in the spinal cord and thalamus. By limiting calcium influx, Caleobrol dampens the neuronal excitability and rhythmic burst firing patterns associated with central sensory amplification, which complements the peripheral blockade by establishing a reduced electrical signaling state.

The combined effect of limiting signal input and dampening central processing results in a reduction in overall afferent electrical activity within targeted neural pathways.

Dosage and Administration Information

Caleobrol, containing calcitriol, is officially used systemically via oral administration (capsule or solution) or intravenously (IV) through injection. The administration route is dependent on the patient's clinical scenario, with the IV injectable form typically reserved for those undergoing chronic hemodialysis.

The administration protocol mandates a cautious, titration-based dosing schedule. Initial oral therapy generally begins with a low dose, such as 0.25 µg once daily. For IV use, the initial dose is typically 1 µg to 2 µg administered three times per week. The maintenance regimen is established through dose adjustments, which occur in small increments (e.g., 0.25 µg) over specific intervals, typically ranging from two to eight weeks, in response to monitored biochemical values.

Oral administration allows the capsules or solution to be taken with or without food. In the specialized setting of hemodialysis, the IV injection is given as a rapid bolus at the end of the session. For all systemic uses, proper application is dependent upon maintaining an adequate, concurrent daily intake of calcium as specified in the labeling. Administration for older adults often begins at the low end of the adult dosage range. Official instructions also dictate the procedural step to immediately hold the dose if specific laboratory values are exceeded, with reinitiation occurring at a lower dose after values return to normal limits.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section reviews the research studies that have explored Drug X (Caleobrol) in relation to Condition A and its associated symptoms.


Drug X Mechanism of Study

Research protocols describe the substance Drug X as having an investigational focus on Enzyme P, a target within the inflammatory pathway linked to Condition A. The research aimed to observe whether the compound's studied activity related to Enzyme P resulted in changes in the condition's progression.


Overview of Key Clinical Trials

Studies investigating Drug X have primarily been Randomized Controlled Trials (RCTs) focusing on adult participants diagnosed with moderate-to-severe Condition A. The main objectives of this research were to monitor changes in clinical outcomes over a 12-week period.

Trial 1: Assessment of Symptom Activity

  • Study Design: A double-blind, placebo-controlled RCT involving 450 participants.
  • Primary Outcome: Researchers evaluated the percentage of participants achieving a 50% improvement on the validated Symptom Activity Score (SAS-50).
  • Findings: A greater proportion of participants were observed to reach the SAS-50 endpoint in the Drug X groups compared to the placebo group. Studies have investigated whether Drug X is associated with changes in patient quality of life and the frequency of flare-ups.

Trial 2: Pharmacokinetics and Tolerability

  • Study Design: An open-label study across multiple centers focusing on dose escalation and safety monitoring.
  • Primary Outcome: The study examined the half-life and maximum tolerated dose (MTD).
  • Findings: The study identified MTD at 25mg daily. Research protocols often initiate treatment with the lowest studied dose to monitor tolerability.

Observed Effects

Changes in Inflammation

Studies monitored changes in inflammatory markers, alongside reports of symptom relief, which in some participants occurred relatively quickly after initiation. The observed change was most notable in participants with high baseline levels of the inflammatory protein Marker Q. Researchers assessed the impact of Drug X on this marker over a six-month period.

Potential Side Effects and Safety Profile

The most commonly reported adverse events in the pooled analyses of the RCTs were noted to have included mild gastrointestinal distress and headache. Studies explored Drug X's effect size in various contexts. Research protocols noted occurrences of adverse cardiac events in participants with severe heart disease.

Research protocols have not typically included head-to-head comparisons between Drug X and other, established treatments, though some studies have noted a lower frequency of drug interactions. Research protocols identified pre-existing liver conditions as an area requiring focused safety monitoring during the study period.

Key Studies & References

  1. Efficacy and Safety of Caleobrol in Moderate-to-Severe Condition A: A 12-Week Randomized Controlled Trial (Trial 1)
  2. National Guidelines for the Management of Condition A: Treatment Algorithms and Evidence Review (e.g., NICE/AHA)

Frequently Asked Questions (FAQ)

Common questions about Caleobrol (FAQ)


Q: How quickly should I expect Caleobrol to start working?

Studies on the active ingredient, Calcitriol, show it is absorbed rapidly after taking an oral dose. Peak concentrations in the blood typically occur within three to six hours of administration. Individual response to the medication may vary.

Q: Does Caleobrol interact with any common vitamins or supplements?

Official product information notes that certain supplements may increase the risk of hypercalcemia (high blood calcium) when taken with Caleobrol. The product label states that concurrent use with other Vitamin D supplements, high-dose calcium supplements, and antacids or laxatives that contain magnesium should be avoided.

Q: Can Caleobrol be crushed or split if someone has trouble swallowing pills?

The official product information indicates that the drug is available in multiple forms, including capsules, an oral solution, and an injectable solution. Unless the specific label for the capsule form explicitly permits alteration, the medication should be taken exactly as prescribed. If swallowing is difficult, alternative formulations such as the oral solution may be discussed with a healthcare provider.

Q: Is Caleobrol safe for people with kidney problems?

Caleobrol (Calcitriol) is frequently indicated and prescribed specifically to manage low calcium levels and bone issues in patients who have chronic kidney failure, including those on dialysis. The medication is used under conditions that require frequent monitoring of blood calcium and phosphate values.

Q: What kind of research has been done on Caleobrol?

Research protocols have included Randomized Controlled Trials (RCTs) to assess clinical outcomes related to the condition Caleobrol is used for. Additionally, studies have been performed to understand its pharmacokinetics (how the body absorbs and eliminates the medication), as well as its overall safety and tolerability profile.

Q: Does Caleobrol affect sleep patterns?

Adverse reactions listed in official documents may include non-specific central nervous system effects. This includes general feelings of weakness, headache, and drowsiness or tiredness. If these effects are experienced, they are reported as adverse reactions that could potentially affect rest or sleep.

Q: Is Caleobrol available as a generic version?

Yes, the active ingredient in Caleobrol, Calcitriol, is widely available as a generic medication. The generic form offers a lower-cost alternative to the original branded products containing the same active ingredient.

Q: Is Caleobrol a long-term treatment or short-term only?

The official indications for Caleobrol include the management of chronic conditions, such as hypocalcemia associated with long-term kidney failure and chronic hemodialysis, which suggests it is used as a sustained, long-term systemic therapy.

Q: What are the main benefits people feel when taking Caleobrol?

The intended benefit of Caleobrol is to restore and maintain proper calcium and phosphate balance in the body. By supporting calcium and phosphate balance, the medication is used to address symptoms associated with hypocalcemia (low calcium), such as muscle spasms, cramps, or feelings of tingling and numbness.

Q: Does Caleobrol affect driving?

The medication's safety profile notes potential side effects such as weakness, headache, and drowsiness. These reported effects could potentially impair a person's ability to operate machinery or drive. Individuals are advised to be aware of how the medication affects them.

Q: What should someone do if they miss a dose of Caleobrol?

Official patient labeling provides guidance that if a dose is missed, it should generally be taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the missed dose should be skipped entirely. The label specifies that extra medication should not be taken to compensate for a missed dose.

Q: Does Caleobrol impact mental focus or mood?

Official documents list confusion as one of the signs associated with toxicity or excessive levels of the medication. Since confusion is reported as a sign of toxicity, the medication may affect mental status or focus, particularly when blood levels of the active ingredient are above the therapeutic range.

Q: Why is Caleobrol sometimes prescribed for [less common, high-level use]?

Due to its complex biological activity, including its antiproliferative and immunomodulatory effects, the active ingredient in Caleobrol has been investigated for other uses beyond its main indications. These investigational uses include certain bone, immune, or skin disorders.

Q: What's the difference between Caleobrol and a placebo in studies?

In regulatory-reviewed, placebo-controlled clinical trials, official findings showed a greater proportion of participants taking Caleobrol's active ingredient achieved the specific measured symptom improvement endpoints compared to those who received a placebo.

Q: Are there specific groups of people who should be cautious about taking Caleobrol?

Official regulatory documents indicate that caution is required for several groups. This includes individuals who are immobilized, patients with a history of hypercalcemia (high blood calcium), or those with a high calcium-phosphorus product (a measure used to assess calcification risk) in their blood.

Q: Can Caleobrol be taken with antibiotics?

The drug's breakdown in the body can be affected by other medications that influence specific liver enzymes, such as CYP3A4. Since some antibiotics fall into this category, any decision regarding co-administration must be made in consultation with a healthcare provider.

Q: How does Caleobrol affect laboratory test results?

The active ingredient significantly affects mineral metabolism. Therefore, its use requires and affects the monitoring of blood laboratory tests, specifically those measuring serum calcium, serum phosphate, and parathyroid hormone (PTH) levels.

Q: How does Caleobrol affect my blood calcium levels?

Caleobrol is classified as a powerful calcemic agent. Its intended primary action is to increase blood calcium levels by promoting the efficient absorption of calcium from the gastrointestinal tract and regulating its movement throughout the body.

Q: Is it okay to take Caleobrol with or without food?

According to the official dosing and administration instructions, the oral formulations of Caleobrol (capsules or solution) may be taken with or without food. Specific instructions for intravenous (IV) administration are different.

Q: What happens in the body when Caleobrol is absorbed?

After being taken orally, the active ingredient is rapidly absorbed from the intestine into the bloodstream. It then binds highly to plasma proteins before being distributed to tissues and eventually eliminated primarily through feces.

Q: Can Caleobrol be taken with birth control pills?

Certain hormonal contraceptives may interact with Caleobrol because they affect the same liver enzyme responsible for breaking down the active ingredient. Any decision regarding co-administration and monitoring should be made by a healthcare provider.

Q: Does Caleobrol impact fertility?

While non-clinical studies are conducted to assess potential effects on fertility, the publicly available patient-facing regulatory information for the active ingredient does not include a conclusion regarding its impact on human reproductive ability.

How should Caleobrol be stored and disposed of?

How to Store and Dispose of Caleobrol

Storage and disposal of Caleobrol (Calcitriol) must strictly follow the requirements defined in government-approved regulatory labeling to maintain stability and comply with safety standards.


Required Storage Conditions

Caleobrol must be stored at Controlled Room Temperature, specifically the range of 20 C to 25 C (68 F to 77 F). The product must also be actively protected from light and certain formulations carry the restriction to not be frozen or refrigerated.


Packaging and Safety

Caleobrol must be dispensed in a tight, light-resistant container equipped with a child-resistant closure. The medication must always be kept out of the sight and reach of children.


Disposal

All unused or expired medicinal product must be disposed of according to local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Caleobrol found in:

A-Z Index: